Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Cytokinetics

Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It

Bristol Myers Squibb stock skidded Tuesday, tugging Cytokinetics lower, after Bristol's drug, Camzyos, failed in a heart disease study.

Investors Business Daily

Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged

Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged

Shares of Edgewise Therapeutics and Cytokinetics diverged Wednesday after safety questions highlighted a heart disease study from Edgewise.

Investors Business Daily

Some businesses are now backtracking on DEI. Biopharma cannot afford to and must remain resolute

Some businesses are now backtracking on DEI. Biopharma cannot afford to and must remain resolute

'Leaders must hold the line so that never again are medicines developed for and by only some of us,' writes Cytokinetics CEO Robert Blum.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

How Edgewise, Up 55%, Is Hoping To Edge Out Bristol, Cytokinetics In Heart Disease

Edgewise Therapeutics stock skyrocketed on Thursday after a single dose of its drug improved heart function in cardiomyopathy patients.

Investors Business Daily

Cytokinetics' Wild Ride: CEO Defends Deal That Rattled Wall Street

Cytokinetics stock plummeted on a Royalty Pharma deal for three of its heart disease drugs. Here's what CEO Robert Blum says investors missed.

Investors Business Daily

Cytokinetics Reverses Higher On 'Pristine' Results For Bristol Myers-Rivaling Heart Drug

Cytokinetics said Monday its drug "significantly" improved exercise capacity in HCM patients. On Tuesday, Cytokinetics stock reversed higher.

Investors Business Daily

How Cytokinetics Overcame Two Setbacks And Doubled Its Stock Price Over A Month

Cytokinetics has shucked off two high-profile setbacks, leading CYTK stock to double as it looks to take on Bristol in heart disease.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Dow Jones Falls, Nasdaq Rebounds; JPMorgan Eyes Potential Buy Point

Dow Jones Falls, Nasdaq Rebounds; JPMorgan Eyes Potential Buy Point

JPM stock has done well since clearing a trendline entry within its recent base near 148-149 and has gained as much as 17%.

Investors Business Daily

Cytokinetics Has Clawed Back 105% Over Seven Days. Now It Could Score A Buyout.

Cytokinetics Has Clawed Back 105% Over Seven Days. Now It Could Score A Buyout.

Novartis is closing in on a takeover of Cytokinetics, the Wall Street Journal reported Monday, leading CYTK stock to soar in afternoon action.

Investors Business Daily

Cytokinetics Stock Jumps To Higher RS Level; Shoots Up On Heart Drug Study

Cytokinetics Stock Jumps To Higher RS Level; Shoots Up On Heart Drug Study

A Relative Strength Rating upgrade for Cytokinetics shows improving technical performance.

Investors Business Daily

Why Cytokinetics Is Soaring After A 'Bruising' FDA Meeting For Its Heart Drug

Why Cytokinetics Is Soaring After A 'Bruising' FDA Meeting For Its Heart Drug

A "bruising" FDA meeting for Cytokinetics was actually a blessing in disguise, an analyst said Wednesday as CYTK stock surged.

Investors Business Daily

Cytokinetics CEO: Why It's OK Not Being An Overnight Success

Cytokinetics CEO: Why It's OK Not Being An Overnight Success

Nobody will accuse Cytokinetics of being an overnight success, its chief executive says. But CYTK stock trades with enthusiasm on a near goal.

Investors Business Daily

What 5 Analyst Ratings Have To Say About Cytokinetics

What 5 Analyst Ratings Have To Say About Cytokinetics

Within the last quarter, Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings:

Where Cytokinetics Stands With Analysts

Where Cytokinetics Stands With Analysts

Within the last quarter, Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings:

Get all your
news in one place.

100’s of premium titles.
One news app.

Cytokinetics: Q1 Earnings Insights

Cytokinetics (NASDAQ:CYTK) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cytokinetics missed estimated earnings by 8.51%, reporting an EPS of $-1.02 versus an estimate of $-0.94.

Cytokinetics: Q4 Earnings Insights

Cytokinetics (NASDAQ:CYTK) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Organisations

the Wall Street Journal

Bristol Myers Squibb

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

295,191 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play